Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATY AcuityAds		$1.80	$1.38 ▼ $3.66	$90.92M	1.26	56,165 shs	10,300 shs
INV Innventure	$4.42 +4.5%	$4.87	$3.00 ▼ $18.75	$236.41M	0.18	458,536 shs	91,377 shs
TERN Terns Pharmaceuticals	$6.93 +2.5%	$5.27	$1.87 ▼ $11.40	$606.45M	-0.05	1.15 million shs	1.30 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATY AcuityAds	0.00%	0.00%	0.00%	0.00%	0.00%
INV Innventure	+4.49%	+0.68%	-10.16%	-22.05%	+441,999,900.00%
TERN Terns Pharmaceuticals	+2.51%	-1.70%	+13.79%	+129.47%	-12.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATY AcuityAds	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INV Innventure	2.4684 of 5 stars	3.8	0.0	0.0	0.0	1.0	2.5	0.6
TERN Terns Pharmaceuticals	3.7655 of 5 stars	3.3	1.0	0.0	4.1	1.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATY AcuityAds	0.00	N/A	N/A	N/A
INV Innventure	3.50	Strong Buy	$14.00	216.74% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	125.47% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATY AcuityAds	$121.04M	0.00	N/A	28.83	$1.40 per share	0.00
INV Innventure	$1.22M	193.79	N/A	N/A	$7.97 per share	0.55
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$3.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATY AcuityAds	-$580K	-$0.01	N/A	N/A	N/A	-1.39%	-5.84%	-4.46%	N/A
INV Innventure	-$78.19M	N/A	0.00	N/A	N/A	-20,429.67%	-33.64%	-25.35%	N/A
TERN Terns Pharmaceuticals	-$88.85M	-$1.04	0.00	N/A	N/A	N/A	-27.35%	-26.18%	11/11/2025 (Estimated)

Latest INV, TERN, GVCT, and ATY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	INV Innventure	-$0.17	-$1.60	-$1.43	-$1.60	$0.69 million	$0.48 million
8/5/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATY AcuityAds	N/A	N/A	N/A	N/A	N/A
INV Innventure	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATY AcuityAds	0.04	3.69	3.69
INV Innventure	0.04	0.29	0.11
TERN Terns Pharmaceuticals	N/A	24.70	24.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATY AcuityAds	8.66%
INV Innventure	55.98%
TERN Terns Pharmaceuticals	98.26%

Insider Ownership

Company	Insider Ownership
ATY AcuityAds	11.98%
INV Innventure	23.13%
TERN Terns Pharmaceuticals	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATY AcuityAds	187	56.83 million	50.02 million	Not Optionable
INV Innventure	N/A	53.49 million	41.12 million	N/A
TERN Terns Pharmaceuticals	40	87.51 million	86.20 million	Not Optionable

INV, TERN, GVCT, and ATY Headlines

Recent News About These Companies

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

August 21 at 4:05 PM | globenewswire.com

Disappointing competitor oral GLP-1 data an opportunity for Terns, says Mizuho

August 20 at 6:10 PM | msn.com

5 Oral Obesity Drugs Challenging Lilly’s Orforglipron

August 12, 2025 | biospace.comB

William Blair Has Positive Outlook of TERN FY2025 Earnings

August 9, 2025 | marketbeat.com

Terns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

August 6, 2025 | marketbeat.com

Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market

August 6, 2025 | biospace.comB

Terns to stop funding metabolic disease trials beyond 2025, seeks partners for assets

August 6, 2025 | fiercebiotech.comF

Terns (TERN) Q2 Net Loss Narrows 16%

August 6, 2025 | fool.com

Terns Pharmaceuticals Reports Q2 2025 Financial Results

August 6, 2025 | tipranks.com

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 5, 2025 | globenewswire.com

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

August 4, 2025 | globenewswire.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 3, 2025 | marketbeat.com

Terns Pharmaceuticals (TERN) to Release Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

Obesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-Waiting

July 14, 2025 | biospace.comB

Terns Pharmaceuticals CEO & Director Acquires 98% More Stock

July 4, 2025 | finance.yahoo.com

Terns pharmaceuticals CEO Burroughs buys $90k in shares

June 27, 2025 | investing.com

Rivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

June 26, 2025 | fiercebiotech.comF

Terns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - Nasdaq

June 24, 2025 | nasdaq.com

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - Morningstar

June 24, 2025 | morningstar.comM

Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing

June 23, 2025 | medpagetoday.comM

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

June 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INV, TERN, GVCT, and ATY Company Descriptions

AcuityAds NYSE:ATY

AcuityAds Holdings, Inc. engages in the provision of digital advertising solutions. It operates through the following geographical segments: Unites States, Canada, and Europe and Other. The company was founded by Tal Hayek, Nathan Mekuz, Rachel Kapcan, and Joe Ontman on October 9, 2009 and is headquartered in Toronto, Canada.

Innventure NASDAQ:INV

$4.42 +0.19 (+4.49%)

As of 08/22/2025 04:00 PM Eastern

Innventure Inc. founds, funds and operates companies with a focus on transformative, sustainable technology solutions acquired or licensed from multinational corporations. Innventure Inc., formerly known as Learn CW Investment Corporation, is based in ORLANDO, Fla.

Terns Pharmaceuticals NASDAQ:TERN

$6.93 +0.17 (+2.51%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.06 +0.13 (+1.86%)

As of 08/22/2025 07:55 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time